ATE211487T1 - Dermatansulfatezusammensetzung als antithromotisches mittel - Google Patents

Dermatansulfatezusammensetzung als antithromotisches mittel

Info

Publication number
ATE211487T1
ATE211487T1 AT94927827T AT94927827T ATE211487T1 AT E211487 T1 ATE211487 T1 AT E211487T1 AT 94927827 T AT94927827 T AT 94927827T AT 94927827 T AT94927827 T AT 94927827T AT E211487 T1 ATE211487 T1 AT E211487T1
Authority
AT
Austria
Prior art keywords
antithrmotic
dermatic
agent
agents
combined
Prior art date
Application number
AT94927827T
Other languages
English (en)
Inventor
Akikazu Takada
Junichi Onaya
Mikio Arai
Satoshi Miyauchi
Mamoru Kyogashima
Keiichi Yoshida
Original Assignee
Seikagaku Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seikagaku Kogyo Co Ltd filed Critical Seikagaku Kogyo Co Ltd
Application granted granted Critical
Publication of ATE211487T1 publication Critical patent/ATE211487T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Plant Substances (AREA)
AT94927827T 1993-09-30 1994-09-30 Dermatansulfatezusammensetzung als antithromotisches mittel ATE211487T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP26975893 1993-09-30
PCT/JP1994/001643 WO1995009188A1 (fr) 1993-09-30 1994-09-30 Antithrombotique

Publications (1)

Publication Number Publication Date
ATE211487T1 true ATE211487T1 (de) 2002-01-15

Family

ID=17476745

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94927827T ATE211487T1 (de) 1993-09-30 1994-09-30 Dermatansulfatezusammensetzung als antithromotisches mittel

Country Status (17)

Country Link
US (1) US5801162A (de)
EP (2) EP0671414B1 (de)
JP (1) JP3813169B2 (de)
KR (1) KR950704362A (de)
CN (1) CN1115182A (de)
AT (1) ATE211487T1 (de)
CA (1) CA2150552C (de)
DE (1) DE69429576T2 (de)
DK (1) DK0671414T3 (de)
ES (1) ES2173124T3 (de)
FI (1) FI952593A (de)
HU (1) HU219339B (de)
NO (1) NO308856B1 (de)
PL (2) PL177218B1 (de)
RU (1) RU2153506C2 (de)
SG (1) SG67928A1 (de)
WO (1) WO1995009188A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1274351B (it) * 1994-10-06 1997-07-17 Alfa Wassermann Spa Uso di alcuni glicosaminoglicani nella dialisi peritoneale.
CN1196734A (zh) * 1995-09-19 1998-10-21 生化学工业株式会社 消炎药
AU4996400A (en) 1999-05-10 2000-11-21 The Texas A & M University System A peptide inhibitor of fibrinogen blood clotting
JP2001151680A (ja) * 1999-11-24 2001-06-05 Seikagaku Kogyo Co Ltd 鎮痒剤
JP2001187740A (ja) * 2000-01-05 2001-07-10 Seikagaku Kogyo Co Ltd 創傷治療剤
JP4633232B2 (ja) * 2000-06-22 2011-02-16 生化学工業株式会社 成長因子誘導剤
JP2002080371A (ja) * 2000-06-23 2002-03-19 Seikagaku Kogyo Co Ltd プラスミノーゲンアクチベーター活性促進剤
AU2003243396A1 (en) 2002-06-03 2003-12-19 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from chondroitinase b
CN100384884C (zh) * 2006-05-29 2008-04-30 南京健友生物化学制药有限公司 肝素钠副产物中分离提纯硫酸皮肤素和低分子硫酸乙酰肝素的方法
JP4524296B2 (ja) * 2007-03-30 2010-08-11 生化学工業株式会社 発毛促進剤
JP4881246B2 (ja) * 2007-07-13 2012-02-22 生化学工業株式会社 発毛効果増強剤
IT1401253B1 (it) * 2010-04-23 2013-07-18 Uni Degli Studi Carlo Bo Urbino Uso del sulodexide per la riduzione delle metalloproteinasi di matrice.
WO2013006906A1 (en) * 2011-07-11 2013-01-17 Commonwealth Scientific And Industrial Research Organisation Dermatan sulphate, pharmaceutical compositions and process for producing same
CN109596742B (zh) * 2018-12-25 2022-04-26 深圳市格利科生物科技有限公司 一种检测硫酸乙酰肝素成品中主要成分含量的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2535324A1 (fr) * 1982-10-27 1984-05-04 Choay Sa Station perfectionnee pour l'epuration d'eaux usees
EP0112122B1 (de) * 1982-12-14 1991-08-28 South African Inventions Development Corporation Plasminogenaktivator
JPS59138202A (ja) * 1983-01-27 1984-08-08 Rikagaku Kenkyusho 新規な硫酸化アミノ糖含有多糖及びその製造法
IT1208509B (it) * 1985-03-13 1989-07-10 Mediolanum Farmaceutici Srl Processo per la produzione di eparan solfato e dermatan solfato naturali sostanzialmente puri eloro impiego farmaceutico.
DE3512909A1 (de) * 1985-04-11 1986-10-23 Behringwerke Ag, 3550 Marburg Verfahren zur bestimmung von plasminogenaktivatoren (pa)
IT1214609B (it) * 1985-05-17 1990-01-18 Opocrin Spa Esosaminoglicani solfati depolimerizzati ad attivita'antitrombotica, fibrinolitica, antinfiammatoria, loro procedimento di preparazione e composizioni farmaceutiche che li contengono.
FR2584728B1 (fr) * 1985-07-12 1987-11-20 Choay Sa Procede de sulfatation de glycosaminoglycanes et de leurs fragments
IT1189085B (it) * 1986-03-25 1988-01-28 Mediolanum Farmaceutici Srl Processo per la preparazione di dermatan solfato ad alta purezza e composizioni farmaceutiche che lo contengono
JPH069042B2 (ja) * 1986-09-10 1994-02-02 日本電気株式会社 共用記憶媒体の順次アクセス制御装置
JP2667469B2 (ja) * 1988-10-06 1997-10-27 日本放送協会 撮像管用偏向ヨーク
ATE98656T1 (de) * 1989-10-04 1994-01-15 Akzo Nv Sulfatierte glykosaminoglykuronane mit antithrombotischer wirkung.
US5118793A (en) * 1989-10-20 1992-06-02 Washington University Modified heparin cofactor II
US5382570A (en) * 1990-04-23 1995-01-17 Akzo, N.V. Sulfated glycosaminoglycanoid derivatives of the dermatan sulfate and chondroitin sulfate type
FR2663639B1 (fr) * 1990-06-26 1994-03-18 Rhone Poulenc Sante Melanges de polysaccharides de bas poids moleculaires procede de preparation et utilisation.
CA2070813C (en) * 1990-11-05 1996-10-29 Hendrik Coenraad Hemker A method to determine the concentration of anticoagulants
IT1245761B (it) * 1991-01-30 1994-10-14 Alfa Wassermann Spa Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
IT1251183B (it) * 1991-08-28 1995-05-04 Opocrin Spa Dermatan solfato ad alto titolo, dotato di elevata attivita' trombolitica, e forme farmaceutiche che lo contengono.

Also Published As

Publication number Publication date
DE69429576D1 (de) 2002-02-07
AU7708594A (en) 1995-04-18
EP0671414B1 (de) 2002-01-02
NO308856B1 (no) 2000-11-06
FI952593A (fi) 1995-07-28
NO952137D0 (no) 1995-05-30
SG67928A1 (en) 1999-10-19
KR950704362A (ko) 1995-11-20
AU699371B2 (en) 1998-12-03
PL309218A1 (en) 1995-10-02
FI952593A0 (fi) 1995-05-29
DE69429576T2 (de) 2002-08-22
HUT73245A (en) 1996-07-29
DK0671414T3 (da) 2002-04-22
RU2153506C2 (ru) 2000-07-27
JP3813169B2 (ja) 2006-08-23
PL177218B1 (pl) 1999-10-29
EP0671414A4 (de) 1995-11-15
EP0671414A1 (de) 1995-09-13
CA2150552C (en) 1999-12-21
HU219339B (en) 2001-03-28
US5801162A (en) 1998-09-01
PL177245B1 (pl) 1999-10-29
RU95112534A (ru) 1997-03-20
CN1115182A (zh) 1996-01-17
NO952137L (no) 1995-07-26
HU9501542D0 (en) 1995-07-28
ES2173124T3 (es) 2002-10-16
EP1125977A1 (de) 2001-08-22
WO1995009188A1 (fr) 1995-04-06

Similar Documents

Publication Publication Date Title
Hilgartner et al. The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors
ATE211487T1 (de) Dermatansulfatezusammensetzung als antithromotisches mittel
Green et al. Deep vein thrombosis in spinal cord injury: effect of prophylaxis with calf compression, aspirin, and dipyridamole
SE9404196D0 (sv) New antithrombotic formulation
BR9811825A (pt) Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue
MXPA03010085A (es) Composiciones y su uso en la hiperplasia.
SE8903914D0 (sv) Oral composition for the treatment of inflammatory bowel diseases
UA41398C2 (uk) Спосіб лікування пацієнта і спосіб зниження ризику кровотеч та крововиливів в мозок у хворого, який потребує тромболітичної терапії, фармацевтична комбінація у формі заздалегідь упакованої одиниці і фармацевтична пакувальна одиниця, що складається з цієї комбінації
EA199900499A1 (ru) Фармацевтическая композиция, включающая соединение, обладающее анти-xa активностью, и соединение антагонист агрегации тромбоцитов
UA70919C2 (uk) Композиція для лікування та запобігання артеріальному тромбозу з використанням інгібітора фактора ха окремо або в комбінації з препаратом, що унеможливлює агрегацію тромбоцитів
DE69116380T2 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
Chen et al. Can tranexamic acid and hydrogen peroxide reduce blood loss in cemented total knee arthroplasty?
Levy Hemostatic agents.
DK0856312T3 (da) Anvendelse af trospiumchlorid til fremstilling af et lægemiddel til behandling af blæresygdomme
ATE201823T1 (de) Topische pharmazeutische zusammensetzungen, welche heparin enthalten
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
Bartkowski et al. Combined treatment with antibiotic, heparin and streptokinase—a new approach to the therapy of bacterial osteomyelitis
CO5280202A1 (es) Metodos de tratamiento y metodos de rastreo de farmacos
EP1222854A4 (de) Vermeidung und behandlung von krankheiten, die mit der blutgerinnung in zusammenhang stehen
Francis et al. Thrombin activity associated with indwelling central venous catheters
Khatri et al. Spontaneous arterial thrombosis associated with nephrotic syndrome: case report and review of the literature
EP1240900A4 (de) Medizinische zusammensetzungen zur prävention und behandlung von thrombopathie assoziierenden hämorrhagischen erkrankungen
Loeliger Does dipyridamole have antithrombotic potential?
Nikolova et al. Leg ulcerations due to livedo vasculitis: successful combined therapy with pentoxifylline and nifedipine
RU95116161A (ru) Способ лечения синдрома диссеминированного внутрисосудистого микротромбоза при тяжелой изолированной и сочетанной черепно-мозговой травме

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties